Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Shenqi Sherong Pill · 1 trial · 1 indication
Change in Modified Japanese Orthopaedic Association (mJOA) score (on a scale from 0 to 18, with lower scores indicating greater disability) from baseline at Day 42 after administration; the mJOA which is a clinician administered scale to evaluate four clinical dimensions; motor dysfunction score for upper and lower extremities, sensation loss and sphincter dysfunction.
| Arm | Type | Description |
|---|---|---|
| Shenqi Sherong Pill | EXPERIMENTAL | 6g per bag |
| Placebo | PLACEBO_COMPARATOR | 6g per bag |
| Name | Type | Description |
|---|---|---|
| Shenqi Sherong Pill | DRUG | two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks |
| Placebo | DRUG | two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks |
Inclusion Criteria: Participants can only be selected if they meet all the inclusion criteria 1. Age 18-75 years old (including 18 and 75 years old), gender unlimited; 2. Accord with Western medicine diagnosis standards of Cervical Spondylotic Myelopathy; 3. Accord with Chinese medicine diagnosis ...
Shenqi Sherong Pill is an investigational small molecule therapeutic being developed by HUTCHMED (China) Limited for cervical spondylotic myelopathy, a spinal cord condition caused by compression in the neck. It has been studied in a Phase 3 clinical trial and is not described as approved.
Shenqi Sherong Pill is being developed for the treatment of cervical spondylotic myelopathy. This condition involves compression of the spinal cord in the cervical spine. The drug has been evaluated in a Phase 3 trial in participants with this indication.
Shenqi Sherong Pill is developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is the sponsor of the clinical program for this asset.
Shenqi Sherong Pill has completed a Phase 3 clinical trial. It is an investigational therapy and is not described as approved. The Phase 3 study has been completed, and no active trials are currently listed for this drug.
Shenqi Sherong Pill has been studied in one Phase 3 clinical trial, NCT06377072, titled "Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy." The trial enrolled 428 participants in China, was randomized, double-blind, and placebo-controlled, and has been completed.